SpeeDx Increase Distribution Network
18.3.2021 10:00:00 EET | Business Wire | Press release
SpeeDx have announced signing a new distribution partner, further extending customer access to market-leading SpeeDx Resistance Plus® and Plex PCR® tests. Neogen Diagnostik Sağlık Hizmetleri Ltd Şti will distribute all SpeeDx tests throughout Turkey.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210318005254/en/
“Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.” - Warwick Need, SpeeDx Director of Sales (Graphic: Business Wire)
“We continue to see demand for our key tests and technology around the world,” says Warwick Need, SpeeDx Director of Sales. “Neogen Diagnostik are a great fit for SpeeDx products and we are looking forward to working with them to give Turkish laboratories the opportunity to provide ResistancePlus tests and support the use of Resistance Guided Therapy with their clinician partners.”
In addition to Resistance Plus GC* - combining Neisseria gonorrhoeae (GC) detection with markers for ciprofloxacin susceptibility, and Resistance Plus MG* - simultaneously detecting Mycoplasma genitalium and genetic markers for azithromycin resistance, the SpeeDx sexual health portfolio includes Plex PCR VHS* - a multiplex test for herpes simplex virus (1 and 2), varicella zoster and Treponema pallidum (syphilis), and Plex PCR HSV-1&2, VZV.
SpeeDx are also growing their Respiratory portfolio with the recently launched Plex PCR RespiVirus - a comprehensive multiplex panel for respiratory virus testing, and the soon to be launched Plex PCR SARS-CoV-2 test – a dual target COVID-19 assay for confident detection of all currently known circulating variants. A respiratory bacterial infection testing solution will also be launched this year.
“Neogen Diagnostik is pleased to make Resistance Guided Therapy available to all stakeholders in the Turkey healthcare chain from clinicians and lab specialists to patients through this distributorship deal with SpeeDx. This is absolutely of medical value complementing the rational use of antibiotics when treating patients. SpeeDx solutions will be a real diagnostic tool for clinicians when deciding on the best possible treatment options for their patients,” Abdulmecit Arikan, founder of Neogen Diagnostik, said in a statement.
*available where CE-mark is accepted, not available in the U.S.
About SpeeDx Pty Ltd
Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. SpeeDx has a portfolio of CE-IVD kits for detection of infectious disease pathogens, sexually transmitted infection (STI), and antimicrobial resistance markers. SpeeDx Resistance Plus tests enable Resistance Guided Therapy, improving patient outcomes by empowering practitioners to make informed clinical decisions.
For more information about SpeeDx please see: http://plexpcr.com
About Neogen Diagnostik Sağlık Hizmetleri Ltd Şti
Neogen Diagnostik is a medical company founded by Abdulmecit Arikan, a Molecular Biologist with 18 years of experience in executive positions at a leading multinational diagnostics company and 20+ years corporate experience. Neogen Diagnostik is committed to providing access to advanced technologies used for diagnostic purposes in healthcare, believing that innovative technologies with value-based solutions can eliminate the existing obstacles in molecular diagnostics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210318005254/en/
Contact information
Madeline O’Donoghue
Global Marketing Director
madelineo@speedx.com.au
+61 2 9209 4170
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Completes Majority Acquisition in Italy-Based ISEM Packaging Group for AED 704 Million5.3.2026 23:02:00 EET | Press release
2PointZero Group PJSC (ADX: 2PointZero), a next-generation investment powerhouse focused on energy and consumer sectors, announced today that it has formally completed the transaction to acquire a majority position in ISEM, a leading European packaging group serving beauty, fashion, luxury, nutraceuticals and more, for AED 704 million through a combination of secondary and primary capital earmarked to accelerate organic and inorganic growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305800523/en/ 2PointZero Group completes majority acquisition in Italy-based ISEM Packaging Group for AED 704 million (Photo: AETOSWire) 2PointZero Group now holds 60.8% of ISEM, while Peninsula Capital and minority investors own the remaining 39.2%. This marks the start of a strategic partnership between 2PointZero and Peninsula. Together, the partners will reinforce ISEM’s leadership position with a focus on category and geographic expa
Xsolla Announces Reseller Program to Help Game Developers Unlock New Revenue Streams in Local Markets5.3.2026 19:00:00 EET | Press release
Xsolla, a leading global video game commerce company, today announced the Xsolla Reseller Program, a new product designed to help game developers scale and capture untapped revenue in local markets with no development needed. The program launches with a curated cohort of resellers and distributors in Southeast Asia and Latin America, with expansion into additional regions throughout 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305047070/en/ Graphic: Xsolla As game developers pursue global growth, they face a fundamental infrastructure challenge: billions of dollars in revenue remain untapped in emerging, cash-dependent economies, such as Southeast Asia, Latin America, the Middle East, and North Africa, where players purchase digital content through local distribution partners. In mature digital economies, developers seek to extend their reach and distribute digital inventory at scale through more partners and chan
Xsolla Agency Launches to Empower Creators Across Entertainment-Based Intellectual Property5.3.2026 17:23:00 EET | Press release
Xsolla, a global video game commerce company, today launched Xsolla Agency, a comprehensive service connecting game developers with premium entertainment-based intellectual property (IP). The integrated offering addresses critical challenges for game creators: access to world-class IP, global monetization capabilities, and the operational infrastructure needed to build sustainable businesses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305044119/en/ Graphic: Xsolla Xsolla Agency simplifies access to entertainment-based licenses through expert-led negotiations and industry relationships, offering affordable, monetization-focused deals structured for maximum ROI. Strategic IP partnerships increase discoverability, reduce user acquisition costs, and drive higher player spend through impactful LiveOps events and promotional campaigns. The service is backed by the same commerce infrastructure powering 1,500+ game developers
Onego Bio and Sigma Foods Enter Collaboration to Strengthen Egg Protein Innovation and Supply Resilience5.3.2026 17:00:00 EET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein, and Sigma Foods ("SIGMA"), a leading multinational food company, have entered into a collaboration agreement to evaluate the functionality and commercial potential of Bioalbumen®, a non-animal egg protein made with using precision fermentation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305756400/en/ The partnership focuses on advancing ingredient innovation while addressing urgent challenges in today’s egg supply chain—including volatility, rising prices, and avian flu-related disruptions. Bioalbumen® offers a shelf-stable, animal-free alternative that delivers the same functional, nutritional, and sensory performance as traditional eggs, while helping safeguard supply continuity for food manufacturers. Additionally, this collaboration supports Sigma’s commitment to offering safe, nutritious, and high-quality food, while driving science-based inno
Vertex to Present New Data on JOURNAVX ® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures5.3.2026 17:00:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14 days), demonstrating the potential for JOURNAVX as a core element of opioid-free multimodal treatment for moderate-to-severe acute pain after aesthetic and reconstructive procedures. In contrast, the literature shows opioid-free rates of less than 10% with multimodal treatment without JOURNAVX. These data will be presented at the American Academy of Pain Medicine (AAPM) PainConnect 2026 meeting, March 5-8, 2026, in Salt Lake City, UT. This Phase 4 open-label, multicenter, single-arm study evaluated JOURNAVX w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom